TBS Pharma - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 120,732 | 279,055 | 1,100,546 | 1,537,332 | 1,639,364 | 1,758,954 | 1,589,674 | 1,420,173 |
| Profit before tax | 9,023 | 20,669 | 160,060 | 170,114 | 138,517 | 138,775 | 94,243 | 41,060 |
| Net profit | - | - | - | - | 123,067 | 117,536 | 80,065 | 28,098 |
| Equity | 45,600 | 20,746 | 156,774 | 180,637 | 153,704 | 271,240 | 351,305 | 379,403 |
| Liabilities | - | - | - | - | 431,224 | 547,237 | 650,120 | 406,017 |
| Non-current assets | 795 | 30,243 | 13,779 | 23,887 | 21,054 | 15,124 | 9,983 | 7,451 |
| Current assets | 57,778 | 58,166 | 415,637 | 604,678 | 563,874 | 803,353 | 991,442 | 777,969 |
| Total assets | 58,573 | 88,409 | 429,416 | 628,565 | 584,928 | 818,477 | 1,001,425 | 785,420 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 272,057 | 267,968 | 274,660 |
| Social insurance contributions | - | - | - | - | - | 30,979 | 34,643 | 37,394 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +3.1% | +131.1% | +294.4% | +39.7% | +6.6% | +7.3% | -9.6% | -10.7% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | - | - | - | - | 21.0% | 14.4% | 8.0% | 3.6% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | - | - | - | 80.1% | 43.3% | 22.8% | 7.4% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | - | - | - | 7.5% | 6.7% | 5.0% | 2.0% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 7.5% | 7.4% | 14.5% | 11.1% | 8.4% | 7.9% | 5.9% | 2.9% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | - | 2.8 | 2.0 | 1.9 | 1.1 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 18,110 | 49,245 | 186,007 | 275,345 | 258,848 | 293,159 | 293,476 | 254,361 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
TBS Pharma - Social security debts
The company had no debts to Sodra
TBS Pharma - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-03-19 | 2026-03-22 | 1.67 |
| 2026-02-28 | 2026-03-12 | 1.67 |
| 2026-02-21 | 2026-02-21 | 1.67 |
| 2026-01-01 | 2026-01-23 | 1.67 |
| 2025-12-18 | 2025-12-23 | 1.67 |
| 2025-11-28 | 2025-12-15 | 1.67 |
| 2025-10-30 | 2025-11-25 | 1.67 |
| 2025-10-03 | 2025-10-24 | 1.67 |
| 2025-10-02 | 2025-10-02 | 1.77 |
| 2025-07-28 | 2025-08-25 | 3.81 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
TBS Pharma, UAB, code 303011389, is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In 2025, the company generated revenue of €1.42M and net profit of €28.1K, with a profit margin of 2.0%. Revenue decreased by 10.7% year on year, while the two-year change shows a decline of 19.3%, indicating a softer operating scale than in prior years. Profitability also weakened over the period, as net profit fell from €117.5K in 2023 to €80.1K in 2024 and €28.1K in 2025. Total assets at year-end 2025 stood at €785.4K, supported by equity of €379.4K and liabilities of €406.0K, which implies an equity ratio of 48.3% and debt-to-equity of 1.07x. Asset turnover was 1.81x, ROE was 7.4%, and ROA was 3.6%. Revenue per employee reached €284.0K, while profit per employee was €5.6K.